Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

Hangzhou Diagens Biotechnology / Equity Capital Markets

<ul>
<li>Hangzhou Diagens Biotechnology kicks off HK IPO consisting of 8M H shares. The indicative offer price range is HK$95.60–112.50 per share. The company seeks to raise ~$115M.</li>
<li>The company mainly intends to use IPO proceeds for R&amp;D and commercialization of core product, AI AutoVision, an auxiliary diagnostic software designed to undertake chromosome karyotyping analysis.</li>
<li>During the first three quarters of 2025, the company’s revenue increased 5.6x YoY, driven by medical imaging software and medical devices segment. Gross margin improved, while net loss decreased.</li>
</ul>


Hangzhou Diagens Biotechnology kicks off HK IPO consisting of 8M H shares. The indicative offer price range is HK$95.60–112.50 per share. The company seeks to raise ~$115M.
The company mainly intends to use IPO proceeds for R&amp;D and commercialization of core product, AI AutoVision, an auxiliary diagnostic software designed to undertake chromosome karyotyping analysis.
During the first three quarters of 2025, the company’s revenue increased 5.6x YoY, driven by medical imaging software and medical devices segment. Gross margin improved, while net loss decreased.


Hangzhou Diagens Biotechnology IPO: Poised for Scalable Growth from New AI Imaging Software Launch